Polyneuropathy and myopathy in beta-thalassemia major patients

  • P. Nemtsas
  • M. Arnaoutoglou
  • V. Perifanis
  • E. Koutsouraki
  • G. Spanos
  • N. Arnaoutoglou
  • P. Chalkia
  • D. Pantelidou
  • A. Orologas
Original Article

Abstract

The thalassemias are the most common single gene disorder in the world. Nowadays, the average life expectancy of patients in developed countries has increased significantly, while, there was an increase of complications. We aimed to investigate peripheral neuropathy and myopathy in this patient group using a neurophysiological study. We performed nerve conduction studies and electromyography of upper and lower extremities on 36 beta-thalassemia major (β-thal) patients. The electrophysiological findings were correlated with demographic data and laboratory parameters of the disease. Patients with β-thal present polyneuropathy or myopathy at (50%). Polyneuropathy was detected in (38.9%) and myopathy in (27.8%), while polyneuropathy and myopathy were present at (16.7%) with an overlap of the diseases in 1/3 of the patients. There was not a statistically significant correlation of polyneuropathy and myopathy with age, sex, splenectomy, nor with respect to laboratory parameters, hemoglobin, and ferritin. However, there was a statistically significant correlation of polyneuropathy and myopathy with iron overload, as recorded by the magnetic resonance imaging (MRI) of the heart and the liver. Our findings suggest that iron overload plays a key role in the pathogenesis of polyneuropathy and myopathy in β-thal patients, and performing heart and liver MRI for the prediction of such lesions in an annual basis is warranted.

Keywords

Peripheral neuropathy Electromyography Thalassemia complications Nerve conduction study Neurological complications T2* MRI heart T2* MRI liver 

Notes

Compliance with ethical standards

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

277_2018_3251_MOESM1_ESM.pdf (357 kb)
ESM 1 (PDF 356 kb)

References

  1. 1.
    Rund D, Rachmilewitz E (2005) Beta-thalassemia. N Engl J Med 353(11):1135–1146.  https://doi.org/10.1056/NEJMra050436 CrossRefPubMedGoogle Scholar
  2. 2.
    Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12(2):61–76.  https://doi.org/10.1097/GIM.0b013e3181cd68ed CrossRefPubMedGoogle Scholar
  3. 3.
    Cappellini MD, Cohen A, Eleftheriou A et al. In Guidelines for the clinical management of thalassaemia, 2nd Revised Edition. Nicosia (CY): 2008Google Scholar
  4. 4.
    Nemtsas P, Arnaoutoglou M, Perifanis V et al (2015) Neurological complications of beta-thalassemia. Ann Hematol 94:1261–1265CrossRefPubMedGoogle Scholar
  5. 5.
    Musallam KM, Taher AT, Karimi M, Rachmilewitz EA (2012) Cerebral infarction in beta-thalassemia intermedia: breaking the silence. Thromb Res 130(5):695–702.  https://doi.org/10.1016/j.thromres.2012.07.013 CrossRefPubMedGoogle Scholar
  6. 6.
    Karimi M, Haghpanah S, Pishdad P, Rachmilewitz EA (2016) Frequency of silent cerebral ischemia in patients with transfusion-dependent beta-thalassemia major compared to healthy individuals. Ann Hematol 95(8):1387.  https://doi.org/10.1007/s00277-016-2713-z CrossRefPubMedGoogle Scholar
  7. 7.
    Zafeiriou DI, Kousi AA, Tsantali CT et al (1998) Neurophysiologic evaluation of long-term desferrioxamine therapy in beta-thalassemia patients. Pediatr Neurol 18(5):420–424.  https://doi.org/10.1016/S0887-8994(98)00004-6 CrossRefPubMedGoogle Scholar
  8. 8.
    Stamboulis E, Vlachou N, Drossou-Servou M et al (2004) Axonal sensorimotor neuropathy in patients with beta-thalassaemia. J Neurol Neurosurg Psychiatry 75:1483–1486CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sawaya RA, Zahed L, Taher A (2006) Peripheral neuropathy in thalassaemia. Ann Saudi Med 26(5):358–363.  https://doi.org/10.5144/0256-4947.2006.358 CrossRefPubMedGoogle Scholar
  10. 10.
    Nemtsas PPV, Koutsouraki E, Orologas A, Arnaoutoglou M (2014) Is precautionary neurophysiological monitoring useful for beta-thalassemia patients? Clin Neurophysiol 125:S219.  https://doi.org/10.1016/S1388-2457(14)50720-1 CrossRefGoogle Scholar
  11. 11.
    Barbara E. Shapiro DCP (2005) Electromyography and neuromuscular disorders. ElsevierGoogle Scholar
  12. 12.
    J. K (2013) Electrodiagnosis in diseases of nerve and muscle principles and practice. Oxford University PressGoogle Scholar
  13. 13.
    England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, Cohen JA, Fisher MA, Howard JF, Kinsella LJ, Latov N, Lewis RA, Low PA, Sumner AJ, American Academy of Neurology, American Association of Electrodiagnostic Medicine, American Academy of Physical Medicine and Rehabilitation (2005) Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 64(2):199–207.  https://doi.org/10.1212/01.WNL.0000149522.32823.EA CrossRefPubMedGoogle Scholar
  14. 14.
    Anderson LJ, Holden S, Davis B et al (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22:2171–2179CrossRefPubMedGoogle Scholar
  15. 15.
    Gandon Y, Olivie D, Guyader D et al (2004) Non-invasive assessment of hepatic iron stores by MRI. Lancet 363:357–362CrossRefPubMedGoogle Scholar
  16. 16.
    Christoforidis A, Perifanis V, Spanos G et al (2009) MRI assessment of liver iron content in thalassamic patients with three different protocols: comparisons and correlations. Eur J Haematol 82:388–392CrossRefPubMedGoogle Scholar
  17. 17.
    Vlachaki E, Agapidou A, Spanos G et al (2015) Five years of deferasirox therapy for cardiac iron in beta-thalassemia major. Hemoglobin 39:299–304CrossRefPubMedGoogle Scholar
  18. 18.
    Economou M, Zafeiriou DI, Kontopoulos E, Gompakis N, Koussi A, Perifanis V, Athanassiou-Metaxa M (2006) Neurophysiologic and intellectual evaluation of beta-thalassemia patients. Brain and Development 28(1):14–18.  https://doi.org/10.1016/j.braindev.2005.03.006 CrossRefPubMedGoogle Scholar
  19. 19.
    Ouederni M, Ben Khaled M, Mellouli F et al (2017) Myocardial and liver iron overload, assessed using T2* magnetic resonance imaging with an excel spreadsheet for post processing in Tunisian thalassemia major patients. Ann Hematol 96:133–139CrossRefPubMedGoogle Scholar
  20. 20.
    Rachmilewitz EA, Weizer-Stern O, Adamsky K et al (2005) Role of iron in inducing oxidative stress in thalassemia: can it be prevented by inhibition of absorption and by antioxidants? Ann N Y Acad Sci 1054:118–123CrossRefPubMedGoogle Scholar
  21. 21.
    Yarjanli Z, Ghaedi K, Esmaeili A et al (2017) Iron oxide nanoparticles may damage to the neural tissue through iron accumulation, oxidative stress, and protein aggregation. BMC Neurosci 18:51CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Levi S, Taveggia C (2014) Iron homeostasis in peripheral nervous system, still a black box? Antioxid Redox Signal 21(4):634–648.  https://doi.org/10.1089/ars.2013.5813 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Johnstone D, Milward EA (2010) Genome-wide microarray analysis of brain gene expression in mice on a short-term high iron diet. Neurochem Int 56(6-7):856–863.  https://doi.org/10.1016/j.neuint.2010.03.015 CrossRefPubMedGoogle Scholar
  24. 24.
    Street VA, Bennett CL, Goldy JD, Shirk AJ, Kleopa KA, Tempel BL, Lipe HP, Scherer SS, Bird TD, Chance PF (2003) Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 60(1):22–26.  https://doi.org/10.1212/WNL.60.1.22 CrossRefPubMedGoogle Scholar
  25. 25.
    Cuesta A, Pedrola L, Sevilla T, García-Planells J, Chumillas MJ, Mayordomo F, LeGuern E, Marín I, Vílchez JJ, Palau F (2002) The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet 30(1):22–25.  https://doi.org/10.1038/ng798 CrossRefPubMedGoogle Scholar
  26. 26.
    Munoz J, Ferrari N, Kuriakose P (2011) Iron-overload myopathy. Int J Hematol 94(6):503–504.  https://doi.org/10.1007/s12185-011-0961-1 CrossRefPubMedGoogle Scholar
  27. 27.
    Rivella S, Rachmilewitz E (2009) Future alternative therapies for beta-thalassemia. Expert Rev Hematol 2(6):685–697.  https://doi.org/10.1586/ehm.09.56 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Makis A, Hatzimichael E, Papassotiriou I, Voskaridou E (2016) 2017 clinical trials update in new treatments of beta-thalassemia. Am J Hematol 91(11):1135–1145.  https://doi.org/10.1002/ajh.24530 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.First Department of NeurologyUniversity General Hospital of Thessaloniki AHEPAThessalonikiGreece
  2. 2.First Propedeutic Department of Internal MedicineUniversity General Hospital of Thessaloniki AHEPAThessalonikiGreece
  3. 3.Tomographia Diagnostic CenterThessalonikiGreece
  4. 4.Department of PsychiatryUniversity of OxfordOxfordUK
  5. 5.Thalassemia UnitUniversity General Hospital of Thessaloniki AHEPAThessalonikiGreece

Personalised recommendations